Earli Inc.

earli has an ambitious mission: to detect and then treat cancer at its earliest stages, effortlessly and painlessly. in other words, we aim to make cancer a benign experience. our science is based on a new method of detecting, localizing and then treating cancer, developed by dr. sam gambhir, who runs stanford’s canary center for early cancer detection and stanford hospital’s radiology division. earli is starting what we believe will be a new era of “synthetic biomarkers.” rather than searching for often hard-to-detect or not existent natural cancer biomarkers in blood samples using complex chemistry, earli’s technology forces cancer cells, if they exist, to produce non-human molecules they otherwise would not naturally make. as a result, such synthetic biomarkers are readily detectable and quantified, using biology as a diagnostic platform. the same platform can then be used for localization at the intra-organ level, and for treatment. other diseases beyond cancer, are potentially a